

# Viread® Registration In The Developing World

## Approved

1. Argentina	December 2003	25. El Salvador	December 2008	49. Nepal	September 2014
2. Armenia	October 2008	26. Ethiopia	July 2006	50. Niger	January 2008
3. Aruba	July 2011	27. Gabon	March 2007	51. Nigeria	August 2006
4. Azerbaijan	May 2009	28. Georgia	September 2009	52. Pakistan	January 2013
5. Bangladesh	April 2010	29. Ghana	July 2005	53. Panama	June 2010
6. Belarus	August 2008	30. Guatemala	September 2008	54. Paraguay	November 2009
7. Benin	April 2010	31. Guinea	March 2007	55. Peru	August 2008
8. Bhutan	January 2012	32. Guyana	December 2008	56. Philippines	March 2014
9. Bolivia	November 2009	33. Honduras	July 2008	57. Senegal	February 2008
10. Botswana	June 2005	34. Ivory Coast	January 2012	58. Sint Maarten	June 2016
11. Brazil	June 2003	35. Jamaica	January 2009	59. South Africa	April 2007
12. Burkina Faso	April 2008	36. Kenya	January 2005	60. Tanzania	September 2007
13. Cameroon	February 2009	37. Kyrgyzstan	January 2011	61. Thailand	August 2006
14. Central African Republic	March 2008	38. Laos	December 2008	62. Togo	June 2007
15. Chad	February 2012	39. Madagascar	October 2017	63. Trinidad & Tobago	April 2008
16. Chile	September 2006	40. Malawi	May 2007	64. Turkmenistan	February 2009
17. Colombia	July 2010	41. Mali	March 2008	65. Uganda	September 2005
18. Congo, Dem. Rep. of the	August 2015	42. Mauritania	July 2007	66. Ukraine	May 2008
19. Congo, Rep. of the	April 2008	43. Mauritius	April 2006	67. Uruguay	January 2006
20. Costa Rica	May 2011	44. Mexico	August 2004	68. Uzbekistan	December 2009
21. Curacao	September 2009	45. Moldova	December 2007	69. Venezuela	February 2014
22. Dominican Republic	April 2016	46. Mongolia	September 2014	70. Zambia	September 2006
23. Ecuador	August 2012	47. Mozambique	April 2009	71. Zimbabwe	June 2009
24. Egypt	March 2012	48. Namibia	July 2005		

## Terms and Definitions

**Approved:** Dossier submitted and approved by country or no formal regulatory process in place; approval confirmed by country.

**Filed:** Dossier submitted and review pending.

## Note

There can be no guarantee that marketing approval for Viread® will be granted in any of the low- and middle-income countries where registration is pending; any marketing approval, if granted, may have significant limitations on its use.